Navigation Links
Intensive cholesterol therapy with multiple drugs effective over long term
Date:6/25/2012

MAYWOOD, Ill. - For the first time, a study has found that intensive cholesterol therapy involving a combination of drugs for 20 years may be more effective over the long run than taking a single statin medication.

Loyola University Health System cardiologist Binh An P. Phan, MD, FACC, is lead author of the study, which he presented at the National Lipid Association 2012 Annual Scientific Sessions. Phan is director of Loyola's Preventive Cardiology & Lipid Program.

Previous studies have documented the short-term benefits of taking a combination of two or three cholesterol drugs aimed at aggressively lowering LDL (bad cholesterol) and raising HDL (good cholesterol). The new study is the first to show such benefits are maintained over a period of 20 years.

Compared with patients who took a single statin, patients who received a combination-drug therapy had dramatically lower levels of LDL and triglycerides, higher HDL and less fatty buildup in the carotid artery.

At the start of the study, both groups had a similar age and fatty buildup in their blood vessels. After 20 years, the group taking the combination therapy had a "vascular age" that was 10.2 years younger than the group taking a single statin.

Vascular age reflects how old an individual's blood vessels appear to be, based on risk factors and the amount of plaque buildup; it can be higher or lower than an individual's chronological age. In the single-medication group, the average vascular age at the end of the study was 84, or 20 years older than the patients' average chronological age. In the intensive therapy group, the vascular age was 74, only 7 years older than the average chronological age.

Phan and colleagues examined data from the Familial Atherosclerosis Treatment Study (FATS). The study divided patients with extremely high cholesterol into three groups: One group took the statin medication lovastatin (Mevacor) plus a medication called colestipol that binds to cholesterol. A second group took colestipol plus niacin. A third group took a placebo.

At the time of the FATS trial, lovastatin and other statins were still unproven. Statins have since become standard therapy to lower cholesterol. They work by blocking a chemical in the liver needed to make cholesterol.

Upon completion of the initial phase of FATS, some patients agreed to continue to be followed in an observational study, which lasted for 20 years.

In this observational study, one group received a single statin and the other group received intensive combination therapy. For the first 11 years, the intensive therapy consisted of lovastatin, niacin and colestipol. After 11 years, the regimen was changed to either lovastatin or simvastatin (Zocor), plus niacin. By the end of the study, 43 patients in the intensive therapy group were still being followed, and 26 patients in the single-medication group were still being followed.

After 20 years, the intensive therapy group had a LDL cholesterol level of 85 milligrams per deciliter, while the single-medication group had an LDL level of 103 mg/dL. The intensive therapy group also had lower levels of triglycerides (116 mg/dL vs. 167) and higher levels of good HDL (56 mg/dL vs. 46).

Researchers conducted an ultrasound exam to measure fatty buildup in the carotid artery, called carotid intima-media thickness (CIMT). The CIMT was 17 percent thicker in the single-medication group than in the intensive combination therapy group (1.056 mm vs. 0.902 mm). Researchers used this finding to calculate that the single-medication group ended the study with a much higher vascular age.

"These findings are the first to illustrate the benefits of long-term intensive combination lipid [cholesterol] therapy for 20 years in patients with atherosclerotic disease," Phan and colleagues wrote.


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. VCU researchers identify changes in cholesterol metabolic pathways
2. Cholesterol Levels Vary Widely by Country: Study
3. Eliminating the good cholesterol receptor may fight breast cancer
4. U.S.A. Hurdle Specialist Kellie Wells has Joined Elite Athletes Tiger Woods, Hines Ward and Takaishi Saito in Using Cell Therapy
5. HCRI Recognized as Center of Innovation for Stuttering Therapy
6. New drugs, new ways to target androgens in prostate cancer therapy
7. RLIP76 contributes to pancreatic cancer cell resistance to chemotherapy and radiation
8. Anti-cocaine vaccine described in Human Gene Therapy Journal
9. Pediatric regime of chemotherapy proves more effective for young adults
10. Chemotherapy effective for patients with resected SCLC or large-cell neuroendocrine carcinoma
11. Quality of life study shows stereotactic ablative radiotherapy effective treatment; stage I NSCLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... According to an article ... a weight loss dietary supplement, is being recalled due to the discovery that it ... there is not a single supplement on the market proven to help people safety ...
(Date:2/11/2016)... ... February 11, 2016 , ... Dr. ... range of cosmetic procedures. Along with performing procedures, the magazine also highlights that ... many cosmetic procedures. One of the most common procedures he performs is his ...
(Date:2/11/2016)... ... ... The president released a FY 2017 budget request on Tuesday that includes $48.8 ... burden to military beneficiaries. , MOAA’s president, retired Air Force Lt. Gen. Dana ... quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , “We were hoping to ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... dermatology and women’s health, is pleased to announce the promotions of Allison Kelly ... sales team, Steve Catone to executive vice president of North American capital sales, ...
(Date:2/11/2016)... Mount Laurel, NJ (PRWEB) , ... February 11, ... ... Commission) announces the call for nominations seeking candidates for the Board of Commissioners. ... individuals with passion, skills and experience with diversity of clinical practice settings and ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 11, 2016 Transformational M&A achieved through ...   --> Transformational M&A achieved through NPS and ... --> Transformational M&A achieved through NPS and Dyax ... Positioned for future growth with most robust pipeline in Shire ... for future growth with most robust pipeline in Shire ...
(Date:2/11/2016)... Brain Cancer patients in the Mid-South now ... Cancer Center . Optune™, a portable device ... replication causing death of cancer cells, is the first ... a significant extension in overall survival rates for newly ... Center is the only medical center in ...
(Date:2/11/2016)... Jeffrey Zucker , vice president of Feasibility and ... year,s Summit for Clinical Operations Executives (SCOPE), being held Feb. ... Zucker will discuss how sponsors can rebuild and ... Site Study Activation and Performance" portion of the conference. His ... a.m. --> --> In ...
Breaking Medicine Technology: